Recent Finacing
Recent Raise
Respira Therapeutics develops high-efficiency dry powder inhaler (DPI) technology and is transitioning to drug–inhaler product development, reporting 2–4× lung delivery efficiency in preclinical/early clinical testing.
Focus Areas
Recent Investors
Funding round
Investors